Tyra Biosciences (TYRA) EBITDA (2020 - 2026)

Tyra Biosciences has reported EBITDA for 7 years, with the latest figure at -$39.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 40.25% year-over-year to -$39.6 million; the trailing twelve-month figure through Mar 2026 stood at -$131.7 million (down 37.54% YoY), and the FY2025 full-year result was -$120.3 million, down 39.76% from the prior year.
• EBITDA for Q1 2026 stood at -$39.6 million, down from -$33.9 million in the prior quarter.
• The five-year high for EBITDA was -$11.9 million in Q1 2023, with the low at -$39.6 million in Q1 2026.
• Historically, EBITDA has averaged -$22.0 million across 5 years, with a median of -$21.2 million in 2023.
• Annual changes were most pronounced in 2022 — EBITDA plunged 252.27% — and 2023, when it increased 19.91%.
• Tyra Biosciences' EBITDA stood at -$15.0 million in 2022, then sank by 49.48% to -$22.4 million in 2023, then decreased by 18.28% to -$26.6 million in 2024, then fell by 27.61% to -$33.9 million in 2025, then retreated by 16.85% to -$39.6 million in 2026.
• The last three EBITDA figures came in at -$39.6 million (Q1 2026), -$33.9 million (Q4 2025), and -$29.9 million (Q3 2025), per Business Quant data.